John H. Stewart named center director of LSU Health New Orleans/LCMC Health Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John H. Stewart was named center director of the LSU Health New Orleans/LCMC Health Cancer Center. 

He will also join the LSU Health New Orleans School of Medicine faculty as a professor of surgery.

Stewart will set the overall mission, vision and direction for multidisciplinary cancer care and cancer clinical research programs for LSU Health New Orleans and LCMC Health in his new leadership role. 

He and his team will develop a robust cancer clinical trials program, leverage resources to build an innovative targeted cancer research enterprise and create a comprehensive community outreach and engagement program to reduce cancer risk behaviors and cancer incidence. 

Initiatives will integrate disease-specific research and care delivery into a comprehensive patient-oriented approach to benefit patients of Louisiana and surrounding regions, including those currently underserved in accessing leading-edge cancer care.

Stewart, originally from Shreveport, was recruited from the University of Illinois College of Medicine in Chicago. There, he was a University of Illinois Presidential Scholar, professor of surgery in the College of Medicine, deputy director of the University of Illinois Cancer Center, and physician executive for oncology sciences at the University of Illinois Health.

Stewart’s role will be effective July 1.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login